PMPRB report reviews new drugs and their potential impact on future drug spending in Canada

The latest edition of Meds Pipeline Monitor provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may significantly impact clinical practice or drug spending in the coming years.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top